Please consult the Summary of Product Characteristics for full prescribing information.


LIXIANA® is indicated for:1

Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults

Dosing and dose reductions

View LIXIANA® dosing information

Switching to and from LIXIANA®

Guidance for switching patients to and from LIXIANA®

Populations at higher risk of bleeding

Information on patients in whom LIXIANA® is contraindicated

Special populations

Guidance for use of LIXIANA® in patients with renal or hepatic impairment and those receiving concomitant treatment with P-gp inhibitors

Perioperative management

Guidance for patients receiving LIXIANA® who require surgery

Temporary discontinuation or overdose

Guidance in case a patient overdoses or needs to stop taking LIXIANA® temporarily

Adverse events

View details of common adverse events observed in clinical trials with LIXIANA®

Management of bleeding complications

Guidance for management of patients who bleed while receiving LIXIANA®

Coagulation testing

Routine anticoagulation testing is not required with LIXIANA® treatment

Patient alert card

Patients will receive a patient alert card in the box with their tablets

Reference (click to access full publication)